Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Meisel, Roland  [Clear All Filters]
2024
Frangoul H, Locatelli F, Sharma A, Bhatia M, Mapara M, Molinari L, Wall D, Liem RI, Telfer P, Shah AJ, et al. Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024.
Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, De La Fuente J, Shah AJ, Carpenter B, Kwiatkowski JL, et al. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. N Engl J Med. 2024.
Meissner B, Lang P, Bader P, Hoenig M, Müller I, Meisel R, Greil J, Sauer MG, Metzler M, Corbacioglu S, et al. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression. Bone Marrow Transplant. 2024.
Maier C-P, Klose C, Seitz CMartin, Heubach F, Döring M, Meisel R, Schuster FR, Gruhn B, Keller F, Rabsteyn A, et al. Influence of ATLG Serum Levels on CD3/CD19-depleted Hematopoietic Grafts and on Immune Recovery in Pediatric Haplo-HSCT. Blood Adv. 2024.
2023
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HBjörk, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, et al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023:JCO2201630.
Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Bennstein SB, Weinhold S, Degistirici O, Oostendorp RAJ, Raba K, Kögler G, Meisel R, Walter L, Uhrberg M. Corrigendum: Efficient generation of IL-22-secreting ILC3 from CD34+ hematopoietic progenitors in a human mesenchymal stem cell niche. Front Immunol. 2023;14:1292209.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.
Meisel R. Secondary Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease Inform Gene Therapy Approaches. J Clin Oncol. 2023:JCO2300403.
2022
Albert MH, Sirait T, Eikema D-J, Bakunina K, Wehr C, Suarez F, Fox MLaura, Mahlaoui N, Gennery AR, Lankester AC, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Blood. 2022.
Albert MH, Slatter MA, Gennery AR, Güngör T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, Aiuti A, et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood. 2022.
Chandrakasan S, Chandra S, Prince C, Kobrynski L, Lucas L, Patel K, Walter JEszter, Buckley RH, Meisel R, Ghosh S, et al. HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh. Blood Adv. 2022.
2021
Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Stary J, Locatelli F, et al. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021.
2019
Pichler H, Lawitschka A, Glogova E, Willasch AM, von Luettichau I, Lehrnbecher T, Matthes-Martin S, Lang P, Bader P, Sykora KW, et al. Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia - A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP. Am J Hematol. 2019.
Merker M, Salzmann-Manrique E, Katzki V, Huenecke S, Bremm M, Bakhtiar S, Willasch A, Jarisch A, Soerensen J, Schulz A, et al. Clearance of hematological malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions. Biol Blood Marrow Transplant. 2019.
Hoell JI, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, et al. Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. Blood Adv. 2019;3(20):3143-3156.
2015
Kuhlen M, Hönscheid A, Loizou L, Nabhani S, Fischer U, Stepensky P, Schaper J, Klapper W, Siepermann M, Schuster F, et al. De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly. Clin Immunol. 2015.
2014
Meisel R, Heseler K, Nau J, Schmidt SKathrin, Leineweber M, Pudelko S, Wenning J, Zimmermann A, Hengel H, Sinzger C, et al. Cytomegalovirus Infection Impairs Immunosuppressive and Antimicrobial Effector Functions of Human Multipotent Mesenchymal Stromal Cells. Mediators Inflamm. 2014;2014:898630.
2013
Lehmberg K, Albert MH, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, et al. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. Haematologica. 2013.